Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drugFirst approved 2019

Vyndamax(Tafamidis)Pfizer Inc. logoPFE

Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Pfizer Inc.

$2.83B

Medicare cost, 2024

Medicare drug plans spent $2.8 billion on Vyndamax (tafamidis) in 2024, for 109,373 prescriptions and refills filled by 13,925 patients. It ranks 16th among all drugs by Medicare drug plan spending. Spending rose 110% from 2023 to 2024. At about $25,882 per prescription it is a high-cost drug.

Medicare cost, 2024

$2.83B

+109.8% from 2023

Prescriptions

109K

$25,882.18 per claim

Patients

14K

4,416 prescribers

Total spending, 2024

$2.83B

$203,289.90 per patient

Questions and answers

How much does Medicare spend on Vyndamax?

Medicare prescription drug plans paid $2.83B for Vyndamax in 2024, for 109,373 prescriptions and refills to 13,925 patients (up 109.8% from 2023). The average cost per claim was $25,882.18.

Which state spends the most on Vyndamax?

New York had the highest Medicare cost for Vyndamax in 2024: $334.4M for 11,451 claims, followed by California ($243.2M).

Who prescribes Vyndamax the most?

Sarah Cuddy, cardiology in Boston, MA, had the highest Medicare cost for Vyndamax in 2024: 1,675 claims costing $39.5M.

Who makes Vyndamax?

Vyndamax is made by Pfizer Inc. (PFE), listed in the Medicare spending data as Pfizer US Pharm.

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

Medicare spending on Vyndamax was $2.83B in 2024, the highest year shown.

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Top prescribers of Vyndamax, 2024

By Medicare drug cost

PrescriberTypeClaimsPatientsCost
Sarah Cuddy Boston, MACardiology1,675189$39.5M
Maureen C Geary New York, NYNurse Practitioner1,057187$37.1M
Brian M Drachman Philadelphia, PACardiology1,013133$28.2M
Margaret O Cuomo New York, NYNurse Practitioner892137$27.2M
Prem Soman Pittsburgh, PACardiology964111$22.5M
Zubair I Shah Kansas City, KSAdvanced Heart Failure and Transplant Cardiology958110$21.1M
Kunal N Bhatt Atlanta, GAAdvanced Heart Failure and Transplant Cardiology75592$18.8M
Mazen A Hanna Cleveland, OHAdvanced Heart Failure and Transplant Cardiology74089$18.2M
Janice Pieretti Philadelphia, PAAdvanced Heart Failure and Transplant Cardiology57289$16.8M
Josef Stehlik Salt Lake City, UTCardiology72576$16.7M
Sabeena Arora Hartford, CTCardiology53794$16.5M
Ronald M Witteles Stanford, CACardiology62164$14.6M
Ahmad M Masri Portland, ORCardiology54870$14.2M
Brett W Sperry Kansas City, MOAdvanced Heart Failure and Transplant Cardiology61171$14.1M
Hanna K Gaggin Boston, MACardiology58171$13.5M
Edward J Miller New Haven, CTCardiology51868$13.4M
Rebecca R Hung Nashville, TNCardiology53163$13.2M
Joban Vaishnav Baltimore, MDCardiology39165$12.7M
Elsy V Navas Naples, FLAdvanced Heart Failure and Transplant Cardiology42961$11.9M
Kaylee M Baker Philadelphia, PANurse Practitioner43260$11.8M
David L Stern Great Neck, NYCardiology40459$11.6M
Richard K Cheng Seattle, WAAdvanced Heart Failure and Transplant Cardiology40147$11.3M
Cesia Maria Gallegos Kattan New Haven, CTCardiology40153$11.2M
Omar K Siddiqi Boston, MACardiology46248$11.1M
Brendan J Carry Danville, PAInternal Medicine49355$10.7M

Prescriber data by year

YearPrescribersClaimsPatientsCost
20222,10034,8435,087$845.0M
20232,92652,3677,586$1.35B
20244,416109,37313,925$2.83B

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
Pfizer US PharmPFE logoPFE109,373$2.83B

Medicaid spending by quarter

Amount reimbursed by state Medicaid programs, all states

Amount reimbursed

Codes

National drug codes (packages)
1
RxNorm concept IDs
2168534, 2168540, 2168542, 2168548
Application numbers
NDA212161

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube